Results 161 to 170 of about 221,736 (298)

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Radiation-Induced Malignancies of the Head and Neck: A Single-Center Population Study and Survival Outcomes. [PDF]

Curr Oncol
Fraccaroli F, Giannini L, Cristofaro V, Alliata A, Cavalieri S, Deganello A.   +5 more
europepmc   +1 more source

Lung carcinomas in Sprague-Dawley rats after exposure to low doses of radon daughters, fission neutrons, or γ-rays [PDF]

, 1989
Chameaud, J., Chmelevsky, D., Kellerer, Albrecht M., Lafuma, J., Masse, R., Morin, M.   +5 more
core   +1 more source

Engineered Mesenchymal Stem Cell–NK Cell Complexes for Spatially Targeted and Functionally Revitalized Cancer Immunotherapy

Advanced Science, EarlyView.
IL‐15‐engineered stem cell–NK cell complexes, assembled via bioorthogonal chemistry, enable effective lung cancer immunotherapy. Abstract Natural killer (NK) cells represent a powerful immunotherapeutic strategy due to their intrinsic cytotoxicity and ability to target tumor cells independently of antigen presentation.
Qian Zhang, Bo Yin, Munaiwaier Sabier, Youlan Yang, Mengling Wu, Zhouping Zhao, Xuanzhi Luo, Yuehong Zhong, Xiuming Zhu, Jie Zhang, Jing Wang, Kai Chen, Fei Ruan, Wei Zhang, Zhimin Lu, Jiong Wang   +15 more
wiley   +1 more source

Assessment of the Advancement of Alveolar Bone Loss in Canine Patients Receiving Definitive Radiotherapy for Sinonasal Tumors. [PDF]

Vet Radiol Ultrasound
Paul-Stewart E, Zukeran-Kerr K, Pinto A, Snyder C, Van Asselt N.   +4 more
europepmc   +1 more source

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

Advanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li, Tao Wang, Yuwen Zhong, Zhiming Wang, Wei Li, Zejian Wang, Xinyi Yang, Yu Qiao, Jianfeng Xiang, Wei Gu, Zishu Wang, Lei Sun, Feng Qian   +12 more
wiley   +1 more source

PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [PDF]

Endocr Relat Cancer
Corbett V, Gupta G, Chauhan A.
europepmc   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source

Radiation-induced meningiomas, cerebral aneurysm, and multiple cavernomas 2 decades after radiotherapy for medulloblastoma: illustrative case. [PDF]

J Neurosurg Case Lessons
Dayrit AA, Amasula AR, Nicer DPC, Khu KJO, Legaspi GD.   +4 more
europepmc   +1 more source

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

Advanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong, Lingshuang Wang, Hui Zhang, Menghuan Li, Zhong Luo, Yan Hu, Chunyuan Cai   +6 more
wiley   +1 more source